Skip Navigation LinksHome > June 1, 2013 - Volume 63 - Issue 2 > Hematologic, Hepatic, Renal, and Lipid Laboratory Monitoring...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e31828d69f1
Brief Report: Clinical Science

Hematologic, Hepatic, Renal, and Lipid Laboratory Monitoring After Initiation of Combination Antiretroviral Therapy in the United States, 2000–2010

Yanik, Elizabeth L. ScM*; Napravnik, Sonia PhD, MPH*,†; Ryscavage, Patrick MD; Eron, Joseph J. MD*,†; Koletar, Susan L. MD§; Moore, Richard D. MD, MHS; Zinski, Anne PhD; Cole, Stephen R. PhD*; Hunt, Peter MD#; Crane, Heidi M. MD, MPH**; Kahn, James MD††; Mathews, William C. MD, MPH‡‡; Mayer, Kenneth H. MD§§; Taiwo, Babafemi O. MBBS‖‖; on behalf of the Center for Aids Research Network of Integrated Clinical Systems (CNICS) Cohort Study

Collapse Box


Abstract: We assessed laboratory monitoring after combination antiretroviral therapy initiation among 3678 patients in a large US multisite clinical cohort, censoring participants at last clinic visit, combination antiretroviral therapy change, or 3 years. Median days (interquartile range) to first hematologic, hepatic, renal, and lipid tests were 30 (18–53), 31 (19–56), 33 (20–59), and 350 (96–1106), respectively. At 1 year, approximately 80% received more than 2 hematologic, hepatic, and renal tests consistent with guidelines. However, only 40% received 1 or more lipid tests. Monitoring was more frequent in specific subgroups, likely reflecting better clinic attendance or clinician perception of higher susceptibility to toxicities.

© 2013 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.